Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 12/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4384901 | 0.78 | IDO1 (0.43) | CLK4KCNA5GRM5IDO1TDO2 | |
| SCHEMBL4383727 | 0.76 | CYP19A1 (0.50) | KCNA5GRM5ALDH1A1IDO1TDO2 | |
| SCHEMBL4409887 | 0.72 | MEN1 (0.37) | KCNA5GRM4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1380955 | 0.72 | CYP19A1 (0.46) | CLK4KCNA5GRM5KDM4EALDH1A1 | |
| SCHEMBL10360256 | 0.71 | TSHR (0.46) | KCNA5GRM4SLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL17488166 | 0.70 | SLC6A3 (0.42) | SLC6A2SLC6A4SLC6A3FFAR1KDM4E | |
| SCHEMBL2939744 | 0.66 | GRM4 (0.44) | CLK4GRM4SLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL13589661 | 0.66 | S1PR1 (0.41) | GRM4FFAR1 | |
| SCHEMBL4083138 | 0.66 | ENPP2 (0.47) | CLK4GRM4SLC6A2SLC6A4ALDH1A1 | |
| SCHEMBL29434770 | 0.65 | TSHR (0.48) | KCNA5GRM4SLC6A2SLC6A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | CLK4 1663/4885KCNA5 184/4885GRM4 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.